Quick Takeaways
- Redmile Group, LLC has 14 issuer positions tracked on this page.
- Estimated disclosed ownership value: $406,878,706.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Redmile Group, LLC
- Location
- Larkspur, CA
- Summary
- The estimated value of insider holdings of Redmile Group, LLC is at least $406,878,706 dollars as of 23 Apr 2026. Redmile Group, LLC is the 10%+ Owner of RayzeBio, Inc. and owns shares of RayzeBio, Inc. stock worth about $116.11M. Redmile Group, LLC is the 10%+ Owner of ADC Therapeutics SA and owns shares of ADC Therapeutics SA (ADCT) stock worth about $105.19M. Redmile Group, LLC is the Director of Absci Corp and owns shares of Absci Corp (ABSI) stock worth about $41.14M. Redmile Group, LLC is the Director, 10%+ Owner of FATE THERAPEUTICS INC and owns shares of FATE THERAPEUTICS INC (FATE) stock worth about $39.56M. Redmile Group, LLC is the 10%+ Owner of Entrada Therapeutics, Inc. and owns shares of Entrada Therapeutics, Inc. (TRDA) stock worth about $31.25M. Redmile Group, LLC is the 10%+ Owner of Zymeworks Inc. and owns shares of Zymeworks Inc. (ZYME) stock worth about $30.58M. Redmile Group, LLC is the 10%+ Owner of Verve Therapeutics, Inc. and owns shares of Verve Therapeutics, Inc. stock worth about $19.37M. Redmile Group, LLC is the 10%+ Owner of Adagio Therapeutics, Inc. and owns shares of Invivyd, Inc. (IVVD) stock worth about $13.39M. Redmile Group, LLC is the Director, 10%+ Owner of Shattuck Labs, Inc. and owns shares of Shattuck Labs, Inc. (STTK) stock worth about $6.92M. Redmile Group, LLC is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $3.36M.
- Signature
- By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Redmile Group, LLC and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: RayzeBio, Inc. ($116,106,625).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Redmile Group, LLC
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| RYZB | RayzeBio, Inc. | 10%+ Owner | $116,106,625 | 19 Sep 2023 | ||
| ADCT | ADC Therapeutics SA | 10%+ Owner | $105,194,110 | +$107,144,341 | +102% | 31 Mar 2026 |
| ABSI | Absci Corp | Director | $41,142,959 | 12 Jun 2024 | ||
| FATE | FATE THERAPEUTICS INC | Director, 10%+ Owner | $39,557,706 | 20 Apr 2026 | ||
| TRDA | Entrada Therapeutics, Inc. | 10%+ Owner | $31,251,176 | 02 Nov 2021 | ||
| ZYME | Zymeworks Inc. | 10%+ Owner | $30,584,956 | 13 Oct 2022 | ||
| VERV | Verve Therapeutics, Inc. | 10%+ Owner | $19,365,300 | 21 Jun 2021 | ||
| IVVD | Adagio Therapeutics, Inc. | 10%+ Owner | $13,394,292 | 10 Aug 2021 | ||
| STTK | Shattuck Labs, Inc. | Director, 10%+ Owner | $6,924,655 | 25 Aug 2025 | ||
| ATRA | Atara Biotherapeutics, Inc. | Director | $3,356,927 | 16 May 2025 | ||
| AUGX | Augmedix, Inc. | Director, 10%+ Owner | $0 | 02 Oct 2024 | ||
| IGMS | IGM Biosciences, Inc. | Director, 10%+ Owner | $0 | 14 Aug 2025 | ||
| SNCE | Science 37 Holdings, Inc. | Former 10% Owner and Director | $0 | 12 Mar 2024 | ||
| MDVL | MedAvail Holdings, Inc. | Director, 10%+ Owner | 16 Jun 2023 |
Insider Transactions Reported by Redmile Group, LLC:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.